arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Q/C TECHNOLOGIES, INC.

QCLS
$0.88 ▼ -0.03 (-3.40%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
55 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

Q/C TECHNOLOGIES, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.2M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -33.3% ↘
FCF / Share $-0.22 ↗
Trailing P/E —
Price / Book 0.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$-1.89K
↓ -100.5% —
Net Income Profit after all expenses
$-1.24M
↓ -10.5% —
Operating Margin Operating profit as % of sales
-205.7%
↓ -16.3% —
FCF / Share Free cash flow per share
$-0.22
↑ +45.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
16
Cash Quality ↑
53

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 55 quarters